Zobrazeno 1 - 10
of 143
pro vyhledávání: '"Conghua Lu"'
Autor:
Yuanyao Dou, Jie Zheng, Jun Kang, Liping Wang, Daijuan Huang, Yihui Liu, Chao He, Caiyu Lin, Conghua Lu, Di Wu, Rui Han, Li Li, Liling Tang, Yong He
Publikováno v:
iScience, Vol 27, Iss 7, Pp 110150- (2024)
Summary: Targeting the stimulator of interferon genes (STING) pathway is a promising strategy to overcome primary resistance to immune checkpoint inhibitors in non-small cell lung cancer with the STK11 mutation. We previously found metformin enhances
Externí odkaz:
https://doaj.org/article/90d459cd566b448a94993e5efd443914
Autor:
Jie Zheng, Yihui Liu, Yong He, Chen Hu, Di Wu, Tao Peng, Chao He, Rui Han, Conghua Lu, Ziyuan Gao, Daijuan Huang, Caiyu Lin, Yuanyao Dou, Yimin Zhang, Fenfen Sun, Weiling Jiang, Guoqing Yin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 6 (2024)
Background The dynamic interplay between tyrosine kinase inhibitors (TKIs) and the tumor immune microenvironment (TME) plays a crucial role in the therapeutic trajectory of non-small cell lung cancer (NSCLC). Understanding the functional dynamics and
Externí odkaz:
https://doaj.org/article/df3ae1a4c0ab46569dbe23bad02953d3
Autor:
Rui Han, Caiyu Lin, Chong Zhang, Jun Kang, Conghua Lu, Yiming Zhang, Yubo Wang, Chen Hu, Yong He
Publikováno v:
iScience, Vol 26, Iss 7, Pp 107105- (2023)
Summary: The mechanisms of osimertinib resistance have not been well characterized. We conducted next-generation sequencing to recognize novel resistance mechanism and used cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) models
Externí odkaz:
https://doaj.org/article/094c1990bf8c49ea89af0256c0cba2b9
Autor:
Jie Zheng, Yubo Wang, Chen Hu, Mengxiao Zhu, Jianghua Ii, Caiyu Lin, Conghua Lu, Yuanyao Dou, Chenlong Zhao, Yimin Zhang, Di Wu, Li Li, Huan Tang, Tingting He, Chunxiao Pan, Rui Han, Yong He
Publikováno v:
Thoracic Cancer, Vol 13, Iss 22, Pp 3162-3173 (2022)
Abstract Background Circulating tumor DNA (ctDNA) has made a breakthrough as an early biomarker in operable early‐stage cancer patients. However, the function of ctDNA combined with cell‐free DNA (cfDNA) as a predictor in advanced non‐small cel
Externí odkaz:
https://doaj.org/article/c70bb457aef44f9c8b501e7b3a6c8a73
Autor:
Conghua Lu, Rui Yu, Chong Zhang, Caiyu Lin, Yuanyao Dou, Di Wu, Yonghong Pan, Tao Peng, Huan Tang, Rui Han, Yong He
Publikováno v:
Cell Death Discovery, Vol 8, Iss 1, Pp 1-10 (2022)
Abstract Lorlatinib is a promising third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) that has been approved for treating ALK-positive non-small-cell lung cancer (NSCLC) patients with previous ALK-TKI treatment failures
Externí odkaz:
https://doaj.org/article/1046c50fdf5a495b8b4432792833dd0b
Autor:
Li Li, Zhujun Li, Conghua Lu, Jianghua Li, Kejun Zhang, Caiyu Lin, Xiaolin Tang, Zhulin Liu, Yimin Zhang, Rui Han, Yubo Wang, Mingxia Feng, Yuan Zhuang, Chen Hu, Yong He
Publikováno v:
Communications Biology, Vol 5, Iss 1, Pp 1-14 (2022)
The resistance mechanism of osimertinib, a third-generation EGFR-TKI, is mediated by IL-6 and Laminin α5/FAK signaling. Ibrutinib combined with osimertinib is presented as a strategy for overcoming osimertinib acquired resistance in EGFR mutant NSCL
Externí odkaz:
https://doaj.org/article/92d470bd40864ffaab02b316aff97dc9
Publikováno v:
Thoracic Cancer, Vol 12, Iss 23, Pp 3184-3193 (2021)
Abstract Background Activation of ALK leads to a high level of aerobic glycolysis related to crizotinib insensitivity in anaplastic lymphoma kinase‐positive non‐small cell lung cancer (ALK+ NSCLC). The strategy and mechanism of glycolysis inhibit
Externí odkaz:
https://doaj.org/article/4bb9d66354ef4b3b930a41e96b102ed7
Autor:
Yuanyao Dou, Yimin Zhang, Caiyu Lin, Rui Han, Yubo Wang, Di Wu, Jie Zheng, Conghua Lu, Liling Tang, Yong He
Publikováno v:
Frontiers in Bioengineering and Biotechnology, Vol 10 (2022)
Multiple component integration to achieve both therapy and diagnosis in a single theranostic nanosystem has aroused great research interest in the medical investigator. This study aimed to construct a novel theranostic nanoplatform ferrite and ceria
Externí odkaz:
https://doaj.org/article/f58394e3469e4aa58810278711e8e7b8
Autor:
Zhiguo Wang, Conghua Lu, Kejun Zhang, Caiyu Lin, Fang Wu, Xiaolin Tang, Di Wu, Yuanyao Dou, Rui Han, Yubo Wang, Chao Hou, Qin Ouyang, Mingxia Feng, Yong He, Li Li
Publikováno v:
Frontiers in Molecular Biosciences, Vol 9 (2022)
Background: Non-small-cell lung cancer (NSCLC) with STK11 mutation showed primary resistance to immune checkpoint inhibitors (ICIs). The glucose-lowering drug metformin exerted anti-cancer effect and enhanced efficacy of chemotherapy in NSCLC with KR
Externí odkaz:
https://doaj.org/article/427d4869d8834779a24e9f3b5ef7e665
Publikováno v:
Molecular Oncology, Vol 14, Iss 6, Pp 1152-1169 (2020)
Osimertinib, a third‐generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI), provides marked clinical benefit for patients with EGFR‐activating mutations. Unfortunately, limited treatments exist for patien
Externí odkaz:
https://doaj.org/article/306df442d3814158aac9771a111cee34